Kura Oncology, Inc. (KURA) is a publicly traded Healthcare sector company. As of September 1, 2026, KURA trades at $12.47 with a market cap of $1.13B and a P/E ratio of -3.98. KURA moved -1.42% today. Year to date, KURA is +21.75%; over the trailing twelve months it is +60.13%. Its 52-week range spans $5.41 to $13.90. Analyst consensus is strong buy with an average price target of $28.22. Rallies surfaces KURA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
10 analysts cover KURA: 0 strong buy, 10 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $28.22.
| Metric | Value |
|---|---|
| Price | $12.47 |
| Market Cap | $1.13B |
| P/E Ratio | -3.98 |
| EPS | $-3.18 |
| Dividend Yield | 0.00% |
| 52-Week High | $13.90 |
| 52-Week Low | $5.41 |
| Volume | 3.52K |
| Avg Volume | 0 |
| Revenue (TTM) | $67.48M |
| Net Income | $-278.67M |
| Gross Margin | 0.00% |
10 analysts cover KURA: 0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $28.22.